Medtech Insights, Report on the analysis of the market for interventional oncology devices in Europe

The European market for interventional oncology products will see this humble growth by 2033, led by increasing incidence and prevalence of cancer, cost-effectiveness of ablation and embolization devices compared to surgery, improved reimbursement, changing guidelines, introduction of innovative products, growing popularity of minimally invasive surgeries and growing acceptance of physicians for interventional oncology procedures. However, there will be growth in this market difficult mixed clinical data, increasing price competition and ongoing cost constraints in the region.

This Medtech 360 Report contains comprehensive data and analyzes on the state of the interventional oncology device market in Europe in 2019–2033.

Microwave ablation dominates the ablation device market; however, there are new technologies more and more used.

What is driving growth in the microwave ablation device segment?

How the adoption of cryoablation has changed the market dynamics of microwave devices and RF ablation device segments?

How are you? ANGER devices operating on the market? What has driven or limited their growth in the market?

What strategies are key competitors using to position themselves in this market and what challenges do they face?

What major clinical trials are being conducted and what impact will they have on the interventional oncology market?

Ablation therapy procedures will be continue to grow in indications for liver, kidney and lung cancer.

How does resection compete with ablation techniques? What role do guidelines play in choosing ablation therapy over resection?

How it is RF competes with microwave ablation devices?

What are the advantages and disadvantages of each type of ablation device offered by competitors, and how do these differences affect their adoption in various indications?

What will growth look like for different categories of ablation devices?

DEBsi spheres of radioembolization are visible increasing adoption.

How will the market develop for different categories of embolization devices?

What are the prospects for the adoption of various embolization devices and what factors will influence the penetration of these technologies during the forecast period?

How clinical guidelines and clinical trials will impact adoption DEBand radioembolization spheres?

How are radioembolization spheres adopted by physicians in the European market? How do Holmium-166 radioembolization spheres perform compared to Y90 radioembolization sphere?

Contents